granted
on 04 Mar 2024
Last Applicant/ Owned by
2 Gansevoort Street, 9th Floor
New York
NY
10014
Serial Number
97715574 filed on 13th Dec 2022
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
"150 MG/6ML INJECTION FOR IV"
"150 MG/6ML INJECTION FOR IV" The wording BRIUMVI has no meaning in a foreign language. The color(s) black, dark grey, light blue and gold is/are claimed as a feature of the mark. pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncoRead More
pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies
No 97715574
No Service/Collective Mark
No
No
No
No
No
No
No
No
No
26.19.01 -
Spheres
The mark consists of the text "BRIUMVI" in black above the text "UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV" in dark grey with the "B" in "BRIUMVI" partially surrounded by a light blue sphere edged in gold.
| Status Date | Action Taken |
|---|---|
| 05th Mar 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 04th Mar 2024 | SOU TEAS EXTENSION RECEIVED |
| 04th Mar 2024 | SOU EXTENSION 1 FILED |
| 04th Mar 2024 | SOU EXTENSION 1 GRANTED |
| 05th Sep 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 11th Jul 2023 | PUBLISHED FOR OPPOSITION |
| 11th Jul 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 21st Jun 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 07th Jun 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 06th Jun 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
